Threshold Pharmaceuticals would stop enrollment in a Phase 2 clinical trial

Calif., Oct 11, 2007 - Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) announced that, as part of a planned interim analysis, it would stop enrollment in a Phase 2 clinical trial evaluating the efficacy and safety of glufosfamide in patients with recurrent, sensitive small cell lung cancer... Threshold Pharmaceuticals' Press Release-